A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic gastrointestinal stromal tumors (GISTs) in the last two decades. Imatinib and sunitinib are recommended as first-line and second-line therapies, respectively. However, there is a lack of precision th...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xianhao, Yuan, Weiye, Wang, Chong, Song, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720279/
https://www.ncbi.nlm.nih.gov/pubmed/36479203
http://dx.doi.org/10.3389/fphar.2022.978885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720279/
https://www.ncbi.nlm.nih.gov/pubmed/36479203
http://dx.doi.org/10.3389/fphar.2022.978885

Ejemplares similares